Here are four things to know:
1. Participants will undergo white blood cell collection via a leukapheresis procedure. These cells will be modified to attack cancer; after modification, these cells are called “CAR-T cells.”
2. After two to three weeks, the cells are returned to the patient, at which point they will receive three CAR-T infusions delivered directly into the liver once a week for a duration of 10 weeks.
3. Low dose interleukin-2, a protein produced by T-cells, will be delivered by a portable pump during the T-cell infusion period.
4. At the end of the 10-week period, a final imaging test is performed.
More articles on gastroenterology and endoscopy:
Biggest hepatology breakthroughs in 2016: Nonalcoholic steatohepatitis, primary biliary cholangitis
ASGE comments on 21st Century Cures Act: 3 notes
IBD monitoring index may pave the way for GI mobile health: 3 study insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.